4-(4-(Tert-butoxycarbonyl)piperazin-1-yl)butanoic acid | 1240619-81-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 4-(4-(Tert-butoxycarbonyl)piperazin-1-yl)butanoic acid
• 英文别名: 4-[4-[(2-methylpropan-2-yl)oxycarbonyl]piperazin-1-yl]butanoic acid
• CAS: 1240619-81-1
• 化学式: C₁₃H₂₄N₂O₄
• 分子量: 272.34
• InChiKey: DJWURFPLVBHJDF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  19
• 可旋转键数：
  6
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.85
• 拓扑面积：
  70.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• [EN] TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER<br/>[FR] DÉRIVÉS DE TRIAZOLO[4,5-D]PYRIMIDINE POUR LE TRAITEMENT DE MALADIES TELLES QUE LE CANCER
  申请人：MERCK PATENT GMBH

  公开号：WO2014135244A1

  公开（公告）日：2014-09-12

  Compounds of the formula I, in which R1 and R2 have the meanings indicated in Claim 1, are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

  式I的化合物，其中R1和R2具有权利要求1中指示的含义，是GCN2的抑制剂，可用于治疗癌症。
• Triazolo[4,5-d]pyrimidine derivatives
  申请人：MERCK PATENT GMBH

  公开号：US20160015712A1

  公开（公告）日：2016-01-21

  Compounds of the formula I in which R 1 and R 2 have the meanings indicated in Claim 1 , are inhibitors of GCN2, and can be employed, inter alia, for the treatment of cancer.

  式I的化合物，其中R1和R2的含义如权利要求1所示，是GCN2的抑制剂，可用于治疗癌症等疾病。
• FGFR inhibitor and application thereof
  申请人：Betta Pharmaceuticals Co., Ltd.

  公开号：US11365196B2

  公开（公告）日：2022-06-21

  An azatricyclic compound (as represented by Formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases are provided. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like.

  本发明提供了一种可作为成纤维细胞生长因子受体（FGFR）抑制剂的偶氮三环化合物（如式 I 所代表）及其药物组合物、制备方法和在治疗 FGFR 介导的疾病中的用途。该氮杂环化合物通过参与调节细胞增殖、凋亡、迁移、新生血管形成等多个过程而发挥效果。
• TRIAZOLO[4,5-D]PYRIMIDINE DERIVATIVES FOR THE TREATMENT OF DISEASES SUCH AS CANCER
  申请人：Merck Patent GmbH

  公开号：EP2964649B1

  公开（公告）日：2017-05-10
• FGFR INHIBITOR AND APPLICATION THEREOF
  申请人：BETTA PHARMACEUTICALS CO., LTD.

  公开号：US20210130353A1

  公开（公告）日：2021-05-06

  An azatricyclic compound (as represented by formula I) which acts as an inhibitor of fibroblast growth factor receptors (FGFR), as well as a pharmaceutical composition thereof, a preparation method, and a use therefor in the treatment of FGFR-mediated diseases. The azatricyclic compound exerts an effect by means of participating in the regulation of a plurality of processes such as cell proliferation, apoptosis, migration, neovascularization, and the like. AA %%% Formula (I).